Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRIDA-CT: Recombinant Non-immunogenic Staphylokinase in Acute Ischemic Stroke
NCT07324837Phase 3Recruiting
- Sponsor
- SuperGen, Inc.
- Start
- Jun 2026
- Primary completion
- Nov 2028
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Non-immunogenic staphylokinase with Placebo (2 arms). Primary endpoint: Excellent functional outcome at 90 days. Started Jun 2026; status: recruiting.
02
Drugs
staphylokinase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07324837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07324837.